thiophenes has been researched along with adenosine monophosphate in 61 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.64) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (32.79) | 29.6817 |
| 2010's | 38 (62.30) | 24.3611 |
| 2020's | 2 (3.28) | 2.80 |
| Authors | Studies |
|---|---|
| Rozenberg, MC; Walker, CM | 1 |
| Gurbel, PA; Tantry, US | 1 |
| Cattaneo, M | 3 |
| Rich, JD; Wiviott, SD | 1 |
| Foretz, M; Göransson, O; Hardie, DG; Hawley, SA; McBride, A; Ross, FA; Sakamoto, K; Shpiro, N; Viollet, B | 1 |
| Angiolillo, DJ | 1 |
| Buckland, RJ; Jakubowski, JA; Judge, HM; Storey, RF; Sugidachi, A | 1 |
| Dovlatova, NL; Heptinstall, S; Jakubowski, JA; Sugidachi, A | 1 |
| Dovlatova, N; Heptinstall, S; Johnson, A | 1 |
| Barker, CM; Price, MJ | 1 |
| Angiolillo, DJ; Capranzano, P | 1 |
| Eikelboom, JW; Hirsh, J; Raju, NC | 1 |
| Abu-Fadel, M; Norgard, NB | 1 |
| Gooley, PR; Honeyman, JE; Iseli, TJ; Jorgensen, SB; Kemp, BE; Koay, A; Oakhill, JS; Scott, JW; Stapleton, D; Steinberg, GR; van Denderen, BJ | 1 |
| Akram, F; Akram, S; Postuła, M | 1 |
| Angiolillo, DJ; Bhatt, DL; Gurbel, PA; Jennings, LK | 1 |
| Butt, M; Lip, GY; Shantsila, E; Siddique, A | 1 |
| Blade, CL; Das, K; Das, P; Doby, JB; Mukherjee, D; Oliphant, CS | 1 |
| Franchini, M; Mannucci, PM | 1 |
| Banach, M; Hannam, S; Kowalczyk, M; Mikhailidis, DP; Rysz, J | 1 |
| del Río, A; Heras, M | 1 |
| Jilma, B; Krumphuber, J; Siller-Matula, JM | 1 |
| Cattaneo, M; Podda, GM | 1 |
| Frisbie, RK; Geoghegan, KF; Harris, MS; Hoth, LR; Kurumbail, RG; Landro, JA; Qiu, X; Rajamohan, F; Reyes, AR; Valentine, JJ | 1 |
| Fox, SC; Glenn, JR; Heptinstall, S; Iyú, D; Nylander, S; van Giezen, H; White, AE | 1 |
| Fox, SC; Glenn, JR; Heptinstall, S; Iyú, D; White, AE | 1 |
| Frey, N; Ivandic, B | 1 |
| Ağırbaşlı, M; Cinçin, A; Güvenç, H | 1 |
| Storey, RF | 1 |
| Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J | 1 |
| Cattaneo, GJ; Cattaneo, M; Podda, GM | 1 |
| Moliterno, DJ; Rajan, L | 1 |
| Böhm, M; Schirmer, SH | 1 |
| Contractor, H; Ruparelia, N | 1 |
| Dibattiste, PM; Ringwala, SM; Schneider, DJ | 1 |
| Barn, K; Steinhubl, SR | 1 |
| Bernlochner, I; Sibbing, D | 1 |
| Augoustides, JG; Lane, B; Patel, PA | 1 |
| Giugliano, RP; Shimada, YJ | 1 |
| Alves, CM; Caixeta, AM; Carvalho, AC; Carvalho, L; Chan, M; Falcão, FJ | 1 |
| Aylward, PE; Sinhal, AR | 1 |
| Jover, E; Tello-Montoliu, A; Valdés, M | 1 |
| Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ | 1 |
| Sabouret, P; Taiel-Sartral, M | 1 |
| Angiolillo, DJ; Bass, TA; Cho, JR; Darlington, A; Desai, B; Ferreiro, JL; Franchi, F; Guzman, LA; Muñiz-Lozano, A; Patel, R; Rollini, F; Tello-Montoliu, A; Zenni, MM | 1 |
| Caldeira, D; Ferreira, JJ; Pinto, FJ | 1 |
| Chen, ZP; Dite, TA; Galic, S; Issa, SM; Kemp, BE; Langendorf, CG; Ling, N; O'Brien, MT; Oakhill, JS; Scott, JW; Steinberg, GR | 1 |
| Balligand, JL; Balteau, M; Beauloye, C; Bertrand, L; Bontemps, F; de Meester, C; Gélinas, R; Ginion, A; Horman, S; Renguet, E; Sakamoto, K; Timmermans, AD; Vanoverschelde, JL | 1 |
| Adamski, P; Fabiszak, T; Grześk, G; Koziński, M; Kubica, J; Navarese, EP; Ostrowska, M; Paciorek, P | 1 |
| Foretz, M; Schlattner, U; Viollet, B | 1 |
| Borzilleri, KA; Brown, J; Cabral, S; Calabrese, MF; Cameron, KO; Carpino, PA; Caspers, NL; Conn, EL; Frisbie, RK; Geoghegan, KF; Han, S; Harris, MS; Hoth, LR; Kurumbail, RG; Landro, JA; Londregan, AT; Magyar, R; Miller, RA; Qiu, X; Rajamohan, F; Reyes, AR; Sahasrabudhe, PV; Smith, AC; Subashi, TA; Wang, H; Ward, J; Withka, JM | 1 |
| Gogo, P; Keating, FK; Raza, SS; Schneider, DJ; Seecheran, N | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Calabrese, MF; Caspers, NL; Frisbie, RK; Hoth, LR; Kurumbail, RG; Landro, JA; Magyar, R; Rajamohan, F; Reyes, AR; Sahasrabudhe, P; Ward, J; Withka, JM | 1 |
| Chan, DW; Ngan, HY; Yung, MM | 1 |
| Noguchi, T; Roy, B; Shinkai, S; Tsuchiya, Y; Yamamoto, T; Yoshihara, D | 1 |
| Ando, F; Arai, Y; Furusho, T; Isobe, K; Kikuchi, H; Maejima, Y; Mandai, S; Minamishima, YA; Mori, T; Nomura, N; Okado, T; Rai, T; Sasaki, E; Sohara, E; Takahashi, N; Uchida, S; Yamashita, T; Yoshizaki, Y | 1 |
| Barbak, NN; Irmak, NE; Kıbrıs, E | 1 |
| Hussar, DA | 1 |
38 review(s) available for thiophenes and adenosine monophosphate
| Article | Year |
|---|---|
Aspirin and clopidogrel resistance: consideration and management.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Restenosis; Drug Resistance; Humans; Membrane Proteins; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2006 |
Platelet P2 receptors: old and new targets for antithrombotic drugs.
Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Interactions; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2X; Syndrome; Thiophenes; Ticagrelor; Ticlopidine | 2007 |
New antiplatelet therapies for acute coronary syndromes.
Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Blood Platelets; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Treatment Outcome | 2007 |
ADP receptor antagonism: what's in the pipeline?
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2007 |
Pharmacology of emerging novel platelet inhibitors.
Topics: Adenosine; Adenosine Monophosphate; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor | 2008 |
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; History, 20th Century; History, 21st Century; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2008 |
Future prospects in anti-platelet therapy: a review of potential P2Y12 and thrombin receptor antagonists.
Topics: Adenosine Monophosphate; Animals; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Thrombosis | 2008 |
Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases.
Topics: Adenosine; Adenosine Monophosphate; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Imines; Lactones; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptor, PAR-1; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Advances in antiplatelet therapy: agents in clinical development.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Signal Transduction; Thiophenes; Ticagrelor; Treatment Outcome | 2009 |
New antiplatelet drugs: beyond aspirin and clopidogrel.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Emerging P2Y12 receptor antagonists: role in coronary artery disease.
Topics: Adenosine; Adenosine Monophosphate; Animals; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor | 2010 |
New P2Y12 blockers.
Topics: Adenosine; Adenosine Monophosphate; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Treatment Outcome | 2009 |
New antiplatelet agents: why they are needed.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Humans; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Propionates; Pyridines; Thiophenes; Ticagrelor | 2009 |
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.
Topics: Adenosine; Adenosine Monophosphate; Benzofurans; Blood Platelets; Carbamates; Clinical Trials as Topic; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Receptor, PAR-1; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Ticlopidine; von Willebrand Factor | 2010 |
State of the art of new P2Y12 antagonists.
Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
[New approaches and indications for the analysis of platelet function in cardiology].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Novel agents in antiplatelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.
Topics: Adenosine; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Protein Binding; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2011 |
[Myocardial infarction: Role of new antiplatelet agents].
Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Disease Management; Drug Resistance; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Reperfusion; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Time Factors | 2011 |
[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Catheter Ablation; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Update on anti-platelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Thrombolytic Therapy; Ticagrelor | 2011 |
Advances in antiplatelet therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
A brief review of the past and future of platelet P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Thienopyridines and other ADP-receptor antagonists.
Topics: Adenosine; Adenosine Monophosphate; Animals; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Progress in platelet blockers: the target is the P2Y12 receptor.
Topics: Adenosine; Adenosine Monophosphate; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor | 2013 |
Emerging antithrombotic drugs for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Fibrinolytic Agents; Humans; Lactones; Morpholines; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Thiophenes | 2013 |
New antiplatelet agents and the role of platelet function testing in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
[New antiplatelet drugs in coronary artery disease].
Topics: Adenosine; Adenosine Monophosphate; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Double-Blind Method; Dyspnea; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Treatment Outcome | 2014 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2014 |
New antiplatelet agents in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Dyspnea and reversibility profile of P2Y₁₂ antagonists: systematic review of new antiplatelet drugs.
Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Dyspnea; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors.
Topics: Adenosine; Adenosine Monophosphate; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Off-Label Use; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Adenylate Kinase; Biphenyl Compounds; Enzyme Activators; Female; Humans; Ovarian Neoplasms; Pyrones; Signal Transduction; Thiophenes | 2016 |
3 trial(s) available for thiophenes and adenosine monophosphate
| Article | Year |
|---|---|
Effects on platelet function of a direct acting antagonist of coagulation factor Xa.
Topics: Adenosine Monophosphate; Aged; Anticoagulants; Aspirin; Blood Platelets; Coronary Artery Disease; Crotalid Venoms; Factor Xa; Factor Xa Inhibitors; Female; Humans; Lectins, C-Type; Male; Middle Aged; Morpholines; Plant Proteins; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Rivaroxaban; Thiophenes | 2012 |
Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
Topics: Adenosine Monophosphate; Aged; Blood Platelets; Cell Adhesion Molecules; Coronary Artery Disease; Drug Administration Schedule; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Thiophenes; Time Factors | 2014 |
Pharmacodynamic effects during the transition between cangrelor and prasugrel.
Topics: Adenosine Monophosphate; Administration, Oral; Aged; Coronary Artery Disease; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Drug Substitution; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Time Factors; Treatment Outcome | 2015 |
20 other study(ies) available for thiophenes and adenosine monophosphate
| Article | Year |
|---|---|
The effect of pyrimidine compounds on the potentiation of adenosine inhibition of aggregation, on adenosine phosphorylation and phosphodiesterase activity of blood platelets.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Carbon Isotopes; Cyclic AMP; Dipyridamole; Ethanolamines; Ethylamines; Humans; In Vitro Techniques; Morpholines; Phosphoric Diester Hydrolases; Piperidines; Platelet Adhesiveness; Pyrimidines; Thiophenes | 1973 |
Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase.
Topics: Acetyl-CoA Carboxylase; Adenosine Monophosphate; AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Cells, Cultured; Enzyme Activation; Humans; Liver; MAP Kinase Kinase Kinases; Mice; Mice, Knockout; Multienzyme Complexes; Phosphorylation; Protein Binding; Protein Serine-Threonine Kinases; Protein Subunits; Pyrones; Rats; Thiophenes | 2007 |
The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
Topics: Adenosine Monophosphate; Adult; Annexin A5; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytoplasmic Granules; Humans; In Vitro Techniques; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2008 |
The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Cells, Cultured; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2008 |
Multiple electrode aggregometry and P2Y(12) antagonists.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Anticoagulants; Clopidogrel; Dose-Response Relationship, Drug; Electrodes; Equipment Design; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2008 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2008 |
Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes.
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Carbohydrate Metabolism; Catalytic Domain; Chlorocebus aethiops; COS Cells; Enzyme Activation; Glucose; Hepatocytes; Isoenzymes; Mice; Pyrones; Recombinant Proteins; Sensitivity and Specificity; Substrate Specificity; Thiophenes | 2008 |
Escherichia coli expression, purification and characterization of functional full-length recombinant alpha2beta2gamma3 heterotrimeric complex of human AMP-activated protein kinase.
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Biphenyl Compounds; Calcium-Calmodulin-Dependent Protein Kinase Kinase; Catalytic Domain; Cyclic AMP-Dependent Protein Kinase RIIbeta Subunit; Enzyme Activation; Escherichia coli; Homeostasis; Humans; Protein Serine-Threonine Kinases; Protein Subunits; Pyrones; Recombinant Proteins; Thiophenes | 2010 |
Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
Topics: Adenosine; Adenosine Monophosphate; Blood Platelets; Cell Adhesion Molecules; Cells, Cultured; Humans; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, G-Protein-Coupled; Thiophenes; Ticagrelor | 2011 |
Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Cell Adhesion Molecules; Erythrocytes; Humans; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticagrelor | 2011 |
P2Y12 platelet receptors: importance in percutaneous coronary intervention.
Topics: Adenosine; Adenosine Monophosphate; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thienopyridines; Thiophenes; Ticagrelor | 2013 |
Small molecule drug A-769662 and AMP synergistically activate naive AMPK independent of upstream kinase signaling.
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Chlorocebus aethiops; COS Cells; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Molecular Weight; Phosphorylation; Pyrones; Serine; Signal Transduction; Structure-Activity Relationship; Thiophenes | 2014 |
A-769662 potentiates the effect of other AMP-activated protein kinase activators on cardiac glucose uptake.
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Cells, Cultured; Glucose; Insulin; Male; Models, Animal; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Phenformin; Pyrones; Rats; Rats, Wistar; Reactive Oxygen Species; Thiophenes | 2014 |
Bypassing AMPK phosphorylation.
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Pyrones; Signal Transduction; Thiophenes | 2014 |
Structural basis for AMPK activation: natural and synthetic ligands regulate kinase activity from opposite poles by different molecular mechanisms.
Topics: Adenosine Monophosphate; Allosteric Site; AMP-Activated Protein Kinases; Biphenyl Compounds; Drug Delivery Systems; Enzyme Activation; Humans; Kinetics; Ligands; Models, Molecular; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Phosphorylation; Protein Conformation; Protein Isoforms; Pyrones; Structure-Activity Relationship; Surface Plasmon Resonance; Thiophenes | 2014 |
Probing the enzyme kinetics, allosteric modulation and activation of α1- and α2-subunit-containing AMP-activated protein kinase (AMPK) heterotrimeric complexes by pharmacological and physiological activators.
Topics: Adenosine Monophosphate; Allosteric Regulation; AMP-Activated Protein Kinases; Biphenyl Compounds; Enzyme Activation; Enzyme Activators; Enzyme Assays; Humans; Isoenzymes; Kinetics; Protein Structure, Tertiary; Protein Subunits; Pyrones; Recombinant Proteins; Thiophenes | 2016 |
Conformation Control of a Conjugated Polymer through Complexation with Bile Acids Generates Its Novel Spectral and Morphological Properties.
Topics: Adenosine Monophosphate; Bile Acids and Salts; Dimethyl Sulfoxide; Lithocholic Acid; Microscopy, Atomic Force; Molecular Conformation; Molecular Structure; Nanowires; Polymers; Solvents; Spectrophotometry; Thiophenes; Water | 2016 |
Failure to sense energy depletion may be a novel therapeutic target in chronic kidney disease.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Diet, Protein-Restricted; Disease Models, Animal; Energy Metabolism; Fibrosis; Humans; Kidney; Male; Metabolomics; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Myocardium; Pyrones; Renal Insufficiency, Chronic; Signal Transduction; Thiophenes | 2019 |
CHARMM force field generation for a cationic thiophene oligomer with ffTK.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Cations; Computer Simulation; Hydrogen; Models, Molecular; Molecular Conformation; Quantum Theory; Thiophenes | 2021 |
New Drugs 2021, Part 2.
Topics: Adenosine Monophosphate; Alanine; Amisulpride; Carbamates; Cefiderocol; Cephalosporins; Chlorophenols; COVID-19 Drug Treatment; Drug Approval; Drug Combinations; Fumarates; Humans; Indans; Organophosphates; Oxadiazoles; Piperazines; Spiro Compounds; Tetrazoles; Thiophenes; Tromethamine; United States; United States Food and Drug Administration | 2021 |